Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.3.4 replaces the previous Revision: v3.3.3 on the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded New York and Oregon locations in the Locations section and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check49 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; there are no changes to the study details, eligibility criteria, outcomes, or other user-facing content.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; no study details or page content were modified.SummaryDifference0.1%

- Check63 days agoChange DetectedThe government funding status notice banner has been removed from the page. This change does not affect the study details or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check78 days agoChange DetectedNo substantive changes detected on the Study Details page for NCT03650894. The information and layout appear unchanged from the prior state.SummaryDifference0.5%

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.